Covaxin: Submit application for listing of H shares to the China Securities Regulatory Commission.

The announcement of Kexing Pharmaceuticals stated that the company has submitted an application to the Hong Kong Stock Exchange to issue H shares and list them on the main board of the Hong Kong Stock Exchange on November 6, 2025. At the same time, the company has submitted the application materials for this issuance and listing to the China Securities Regulatory Commission, which has recently been received by the Commission. The company still needs to obtain approval or authorization from the China Securities Regulatory Commission, the Securities and Futures Commission of Hong Kong, and the Hong Kong Stock Exchange and other relevant regulatory agencies and securities exchanges for this issuance and listing.